Marlio Charles Mosseri Buys 5,603 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) major shareholder Marlio Charles Mosseri acquired 5,603 shares of the company's stock in a transaction on Friday, June 20th. The stock was purchased at an average cost of $7.99 per share, for a total transaction of $44,767.97. Following the completion of the transaction, the insider now owns 2,981,806 shares in the company, valued at approximately $23,824,629.94. The trade was a 0.19% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Wednesday, June 18th, Marlio Charles Mosseri acquired 28,043 shares of Nuvectis Pharma stock. The shares were acquired at an average cost of $8.05 per share, with a total value of $225,746.15.
• On Tuesday, June 17th, Marlio Charles Mosseri purchased 5,399 shares of Nuvectis Pharma stock. The stock was acquired at an average cost of $8.11 per share, with a total value of $43,785.89.
• On Monday, May 12th, Marlio Charles Mosseri purchased 21,167 shares of Nuvectis Pharma stock. The stock was bought at an average cost of $8.11 per share, with a total value of $171,664.37.
• On Thursday, May 8th, Marlio Charles Mosseri bought 2,650 shares of Nuvectis Pharma stock. The stock was purchased at an average cost of $8.65 per share, with a total value of $22,922.50.
• On Tuesday, May 6th, Marlio Charles Mosseri purchased 12,444 shares of Nuvectis Pharma stock. The shares were purchased at an average cost of $8.59 per share, for a total transaction of $106,893.96.

Nuvectis Pharma Price Performance

NVCT opened at $7.55 on Friday. Nuvectis Pharma, Inc. has a 12 month low of $4.44 and a 12 month high of $11.80. The stock has a market capitalization of $157.72 million, a P/E ratio of -6.68 and a beta of -0.16. The business has a 50 day simple moving average of $9.15 and a 200-day simple moving average of $7.78.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03. Research analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on NVCT. Maxim Group initiated coverage on shares of Nuvectis Pharma in a report on Wednesday, April 2nd. They issued a "buy" rating and a $17.00 target price on the stock. Wall Street Zen raised Nuvectis Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st. Laidlaw started coverage on Nuvectis Pharma in a research note on Monday, March 17th. They issued a "buy" rating and a $19.00 target price on the stock. Finally, HC Wainwright restated a "buy" rating and set a $15.00 price target (up previously from $11.00) on shares of Nuvectis Pharma in a research note on Wednesday, April 30th.

Institutional Trading of Nuvectis Pharma

Institutional investors and hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC purchased a new stake in Nuvectis Pharma in the 4th quarter valued at approximately $34,000. Baxter Bros Inc. raised its holdings in shares of Nuvectis Pharma by 20.0% in the fourth quarter. Baxter Bros Inc. now owns 15,000 shares of the company's stock worth $81,000 after acquiring an additional 2,500 shares during the last quarter. Blue Zone Wealth Advisors LLC purchased a new stake in shares of Nuvectis Pharma in the first quarter valued at $102,000. Squarepoint Ops LLC purchased a new stake in shares of Nuvectis Pharma in the fourth quarter valued at $103,000. Finally, Oppenheimer & Co. Inc. acquired a new stake in shares of Nuvectis Pharma during the fourth quarter valued at $135,000. Hedge funds and other institutional investors own 96.77% of the company's stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.